who can sell semaglutide A South African court has ordered pharmacy group iDexis to stop selling semaglutide-based medicines. The ruling follows a legal challenge by Novo Nordisk, maker of Ozempic and Wegovy. Novo alleged the company GLP-1 Weight Loss Medication -

doi: 10.1186/1550-2783-2-2-38 51

Hypoglycaemia risk is generally low with GLP-1 agonists alone but may be elevated when combined with insulin or sulfonylureas, particularly in patients with poor nutritional status or irregular eating patterns

73 The treatment increased -catenin expression and suppressed RANKL activation, suggesting that semaglutide may promote osteoblastogenesis and inhibit osteoclast-mediated bone resorption through the Wnt signaling pathway

The 0.25mg weekly starting dose is more about getting the body adjusted to the medicine and weight loss seen in the first month is very slight (only 2-4% of initial body weight)